 |
As Venture Capitalist: Quantica SGR – Founder and CEO, Axòn Capital – Founder and Investment Manager, Sofinnova Partners – Venture Consultant, AurorA Science – Founder and Board Member
>15 years comulated as Investor and Board Directror in Life Sciences companies
Investor and Board Member at EOS – Ethical Oncology Science (acquired in 2013 for $470M)
Independent Member of the Research and Innovation Commission at the Italian Ministry of Health
Member of the Assobiotec Steering Committee, the Italian Association for the development of biotechnology
Member of IAB – Italian Angels for Biotech, national business angel association
Member of the ItaliaStartup Board, the Italian Association of Startup Companies
Board Member at Altheia Science, autoimmune diseases and cancer
Member of the Life Sciences Technical Group at Confindustria
 |
Director, San Raffaele-Telethon Institute for Gene Therapy (TIGET) & Division of Regenerative Medicine, Stem Cells & Gene Therapy, San Raffaele Scientific Institute
Professor of “Cell and Tissue Biology” and “Cell and Gene Therapy”, “Vita-Salute San Raffaele” University School of Medicine
Past President of the European Society of Gene and Cell Therapy (ESGCT; 2012-2014)
Member of Board of Directors (2005-08) and Advisory Council of the American Society of Gene and Cell Therapy (ASGCT; 2008-12 )
Author of >250 scientific publications, cumulative IF >2.089 (avg. IF 10.93), h-index 84, >32.700 citations
Inventor of 58 granted and 45 pending patents
Scientific Advisor on EMEA and WHO Committees for the evaluation of novel gene transfer medicines
Awarded the European Research Council (ERC) Advanced Investigator Grant: top EU scientist, 2009
Outstanding Investigator Award from ASGCT in 2014 and from ESGCT in 2015
 |
Physician Scientist
Group Leader, Translational Stem Cell and Leukemia Research Unit, SR-TIGET, Milan, Italy
Staff Haematologist, Hematology and Bone Marrow Transplantation Unit, San Raffaele Hospital, Milan, Italy
International Training
M.D. studies at the University of Heidelberg, Germany, the MD Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA
Internal Medicine Training at Erlangen University Hospital, Germany
Hematology Training at San Raffaele Vita-Salute University, Milan, Italy
Author of >30 scientific publications, cumulative IF>386 (avg. IF 11.23), h-index 16, >1.400 citations; Inventor of 2 patents
2012: Abstract Achievement Award by the American Society of Hematology
2011: Young Investigator Award by ESGCT
2009: Excellence in Research Award by ASGTC
 |
Adverum, Executive VP & CMO
Annapurna, Chief Medical Officer & Head R&D
R&D GSK executive
Head of R&D Rare Disease Unit
Head Development, Alternative Discovery & Development
Head of Development and founding member of GSK R&D Biopharm Unit
Head of Cardiovascular Metabolic Medicine Development Center
General Manager, Founder of GSK internal Biotech Pilot Program, ADP
President & CEO VaxInnate Corporation
Merck Research Laboratories Vaccines – Biologics:
Exec Dir. Head, Department of Global Strategic Regulatory Development for New Vaccines
Faculty and Research Laboratory Head Cornell University Medical College
Columbia University, College of Physicians & Surgeons
Research Fellow, Molecular Immunology, Scripps Research Institute, La Jolla, CA
Founding Member, NIH Geriatrics & Rehabilitative Medicine Study Section
MD and Board Certification in Hematology and Oncology, University of Genoa Medical School, Genoa, Italy
Author of >72 scientific publications
 |
PostDoctoral Researcher – National Institute of Molecular Genetics
Researcher – Nerviano Medical Sciences
PhD Student/PostDoc – San Raffaele Scientific Institute
Second Level Vocational Master (2012 – 2013) in “Pharmacy and Pharmaceutical Oncology” at University of Milan, Italy
International PhD (2008 – 2011) in “Molecular and Cellular Biology” at San Raffaele Vita-Salute
Master Degree in Medical Biotechnology at University of Milan, Italy
Member of the European Academy of Tumor Immunology (EATI)
Author of 17 scientific publications, h-index 12, >700 citation
 |
35 years experience in Chief Financial Officer roles in various biopharmaceutical companies including Oncosec (NASDAQ: ONCS), Biological Dynamics and Genmark Diagnostics (NASDAQ: GNMK)
